Sign in Subscribe
Stocks

Biotech IPOs Face Frosty Reception on Wall Street

Strategic Insights

— 1 min read

Wall Street's enthusiasm for biotechnology initial public offerings (IPOs) appears to be waning, despite the sector's potential for revolutionary healthcare breakthroughs. The number of biotech IPOs has slowed this year, with a total of seven deals raising $948.9 million, nearly one-third of the IPO schedule for 2004. However, several biotech companies with early-stage drugs have seen their shares plummet after going public, with some falling below their issue price.

Key Takeaways:

  • Biotech IPOs have returned 1.9% this year, according to Renaissance Capital, a figure that lags the average 9% return for IPOs this year.
  • The sector's poor performance is attributed to the high risk associated with investing in companies with no hope of profits for another five years.
  • Despite the challenges, investment bankers remain optimistic, arguing that solid young companies can afford to wait for better market conditions.
  • Biotech companies with late-stage drugs, such as Eyetech Pharmaceuticals, have performed relatively well, while those with early-stage drugs, like Xcyte Therapies and Tercica, have seen their shares decline.
  • The sector's woes have led some companies to postpone their IPOs, including Peninsula Pharmaceuticals.

Statistics:

  • The Amex Biotechnology Index soared 290.5% between 1998 and 2000, only to slide 8.5% in 2001 and 41.7% in 2002.
  • Eyetech Pharmaceuticals has soared 55% since its January debut.
  • Xcyte Therapies has seen its shares fall 5% since its debut last week.
  • Tercica has shed 4% since its debut last week.
  • The average return for biotech IPOs is 1.9% this year, compared to the average IPO return of 9%.
  • There have been 7 biotech deals this year, with a total of $948.9 million raised.

Sources:

  • Elizabeth Wine, "Biotech IPOs Face Frosty Reception on Wall Street" (unnamed source, as it appears to be an article written by an expert analyst)
  • Renaissance Capital, cited in the article
  • Cantor Fitzgerald, as cited by Sal Morreale
  • Amex Biotechnology Index, as reported in the article
  • Bloomberg, as cited in the article

(only the sources explicitly mentioned in the provided text)

Read more